PVH
CHRS icon

Psagot Value Holdings’s Coherus Oncology CHRS Stock Holding History

Psagot Value Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27
Closed -$1K – 365
2016
Q1 		$1K Buy
+27
New +$442 ﹤0.01% 366

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Psagot Value Holdings's CHRS Position: Q2 2016 in Review

Psagot Value Holdings sold out of Coherus Oncology (CHRS) in Q2 2016, closing a stake of 27 shares — an estimated $1K sold.

Psagot Value Holdings first reported a position in CHRS in Q1 2016 and held it in 1 quarter. The position peaked at $1K in Q1 2016. 86 funds tracked by Wall St. Rank hold CHRS as of Q2 2016.

  • Psagot Value Holdings reported no remaining Coherus Oncology position as of Q2 2016 after selling out during the quarter.
  • Psagot Value Holdings sold 27 Coherus Oncology shares in Q2 2016, an estimated $1K.
  • Psagot Value Holdings first reported a position in Coherus Oncology in Q1 2016 and held it in 1 quarter.
  • Psagot Value Holdings's Coherus Oncology position peaked at $1K in Q1 2016.
  • 86 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2016.

Based on Psagot Value Holdings's 13F filing for Q2 2016, filed 9 Aug 2016.